CVS Agrees to $315 Million Settlement Over Opioid Prescriptions
The Justice Department accused the pharmacy giant of unlawfully dispensing medically unnecessary opioid prescriptions, contributing to the addiction crisis.
CVS Pharmacy Inc. and its subsidiaries have agreed to pay $315 million to resolve a Justice Department case alleging the company unlawfully dispensed medically unnecessary prescriptions for highly addictive opioids. The settlement aims to address claims that the healthcare giant prioritized profits over public health and safety by providing large quantities of controlled substances.
The lawsuit, initiated in 2024, accused CVS of violating the Controlled Substances Act. Federal officials alleged that the company filled illegitimate prescriptions for potent opioids, often from providers known as "pill mills," which dispensed drugs without a legitimate medical purpose. These prescriptions were frequently billed to and reimbursed by federal healthcare programs, including Medicaid.
According to the Justice Department, poor staffing levels, combined with performance metrics and incentive compensation policies, may have pressured pharmacists to fill prescriptions quickly without adequately verifying their legitimacy. Associate Attorney General Stanley Woodward stated that the settlement represents a significant step in combating the opioid epidemic by holding pharmacies accountable for unlawfully fulfilling prescriptions for controlled substances.
In a statement, CVS maintained that its pharmacists were trained in the safe and appropriate use of all medications and that the company had implemented robust programs to aid them in making sound decisions for patients. The company stated that it strongly disagreed with the lawsuit's claims and that the settlement does not constitute an admission of wrongdoing. CVS also noted in 2024 that pharmacists were being held to "vague, undefined, and ever-changing standards of practice" regarding the filling of opioid prescriptions.
As part of the settlement, CVS is required to implement additional safeguards to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate. This agreement is part of a broader effort by the U.S. government to hold companies accountable for their role in the national addiction and overdose crisis. Over the past decade, various entities within the pharmaceutical industry have reached settlements totaling more than $50 billion with government bodies to address the crisis. The majority of these funds have been allocated to state and local governments, but the federal government has also secured significant settlements with major pharmacies like Walgreens and Walmart in recent years.